Cargando…
Di’ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE(–/–) Mice by Downregulating PCSK9
Numerous risk factors are responsible for the development of atherosclerosis, for which an increased serum level of low-density lipoprotein cholesterol (LDL-C) is a driving force. By binding to the low-density lipoprotein cholesterol receptor (LDLR) and inducing LDLR degradation, proprotein converta...
Autores principales: | Qu, Liping, Li, Didi, Gao, Xiaoping, Li, Yongwei, Wu, Jianming, Zou, Wenjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221936/ https://www.ncbi.nlm.nih.gov/pubmed/30443213 http://dx.doi.org/10.3389/fphar.2018.01170 |
Ejemplares similares
-
Di’ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway
por: Liang, Jiyi, et al.
Publicado: (2022) -
Targeting Energy Protection as a Novel Strategy to Disclose Di’ao Xinxuekang against the Cardiotoxicity Caused by Doxorubicin
por: Wang, Tao, et al.
Publicado: (2023) -
Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris
por: Jia, Yongliang, et al.
Publicado: (2012) -
Comparative Effectiveness of Di'ao Xin Xue Kang Capsule and Compound Danshen Tablet in Patients With Symptomatic Chronic Stable Angina
por: Yu, Yanan, et al.
Publicado: (2014) -
Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients
por: Ma, Liang, et al.
Publicado: (2021)